BriaCell Therapeutics Corp. has reported its financial results for the second quarter and first half of fiscal 2026, revealing a net loss of $7.3 million for the three months ended January 31, 2026, compared to a loss of $6.3 million for the same period in 2025. For the six-month period, the net loss increased to $15.6 million from $12.2 million year-over-year. The company's total operating expenses for the quarter were $7.5 million, up from $7.2 million in the prior year, driven primarily by increased research and development costs associated with its ongoing clinical trials.
The company’s cash and cash equivalents saw a significant increase, rising to $29.9 million as of January 31, 2026, compared to $10.5 million at the end of July 2025. This increase is attributed to successful financing activities, including a public offering that generated approximately $30 million in gross proceeds. BriaCell's total assets also grew to $33.6 million, up from $21.6 million in the previous fiscal year, reflecting a positive working capital balance of $29 million.
BriaCell is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, which is currently under Fast Track Designation by the U.S. FDA. The company has reported positive clinical data, including median overall survival rates that exceed benchmarks for similar patient populations. Additionally, BriaCell is developing its Bria-OTS™ platform for personalized off-the-shelf immunotherapies, with ongoing studies showing promising results.
In terms of operational developments, BriaCell has expanded its workforce to support its clinical operations, resulting in increased wages and salaries, which rose to $1.9 million in the latest quarter. The company has also received a $2 million Small Business Innovation Research grant from the National Cancer Institute to support its Bria-PROS+™ program for prostate cancer. Looking ahead, BriaCell plans to continue its focus on clinical trials and is exploring additional financing options to sustain its operations and development efforts.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer, primarily metastatic breast cancer. Its lead product, Bria-IMT™, is a genetically engineered whole-cell immunotherapy designed to activate the immune system against tumors, often combined with immune checkpoint inhibitors. The company also develops personalized off-the-shelf immunotherapies for multiple cancers. BriaCell relies on third-party manufacturing and targets oncologists and cancer treatment centers globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.